The enrichment of PD-L1+CD8+ double-positive T cells in tumor tissues was less in the oeDT plus pembrolizumab group than in the shDT plus pembrolizumab group (p < 0.05) and the wtT plus pembrolizumab group. This evidence concerns the gene CD8A and neoplasm.